The kidney’s proximal tubule features two distinct segments responsible for glucose reabsorption: the S1 and S2 segments predominantly reabsorb glucose through SGLT2, handling approximately 97% of the filtered glucose load. Meanwhile, the S3 segment engages SGLT1 to reclaim the remaining glucose. While selective SGLT2 inhibitors like dapagliflozin primarily target these early segments, dual inhibition that includes SGLT1 presents an opportunity to influence downstream effects more comprehensively. This approach, until recently, was explored primarily for its potential in diabetes management. However, its implications for blood pressure regulation and renal protection have drawn significant attention owing to the complex interplay between sodium handling, glucose reabsorption, and vascular health.

Salt-sensitive hypertension, a prevalent condition affecting nearly half of hypertensive patients, is characterized by heightened blood pressure responses to excessive dietary salt intake. This pathology not only exacerbates cardiovascular risk but also accelerates kidney damage, ultimately contributing to chronic kidney disease (CKD) progression and renal failure. To model this condition experimentally, researchers utilized established rodent models subjected to high salt diets, mimicking the pathophysiological mechanisms underlying human salt-sensitive hypertension. In this model, the effects of selective SGLT2 inhibition were rigorously compared with those of dual SGLT1/2 inhibition through pharmacological agents dapagliflozin and sotagliflozin, respectively.

Findings demonstrated that while both dapagliflozin and sotagliflozin notably mitigated the severity of salt-induced hypertensive pathology, the dual SGLT1/2 inhibitor produced a more pronounced reduction in mean arterial pressure. This superior efficacy was accompanied by a striking attenuation in kidney injury markers, underscoring the enhanced renal protective capacity of dual inhibition. Interestingly, neither treatment exerted significant effects on blood pressure under normal salt intake, emphasizing the salt-dependent nature of their therapeutic impact. These results suggest a targeted mechanism by which dual inhibition modulates renal sodium and glucose handling, reducing volume overload and subsequent vascular strain.

Further mechanistic insights emerged as researchers observed that sotagliflozin uniquely influenced urinary electrolyte excretion. The drug enhanced sodium and chloride excretion more effectively than dapagliflozin, indicating a potentiation of natriuresis. Additionally, fractional glucose excretion nearly doubled with dual inhibition, signifying a more robust blockade of glucose reabsorption pathways throughout the proximal tubule segments. Despite these metabolic shifts, both drugs preserved overall kidney function, reassuring the renal safety profile of this therapeutic approach. The nuanced metabolic modulation was particularly evident in region-specific alterations in renal lipid metabolism and inflammatory signaling pathways, hallmarks of hypertension-induced kidney injury.

At the molecular level, SGLT2 inhibition demonstrated selective modulation of renal metabolic processes, especially affecting lipid utilization and inflammatory mediators within kidney tissues. These alterations hold substantial significance given the kidney’s high metabolic demands and the role of lipotoxicity in chronic kidney disease progression. By attenuating inflammatory signaling cascades, dual SGLT1/2 inhibition may quell the chronic low-grade inflammation that characterizes hypertensive kidney damage. Such molecular effects complement hemodynamic improvements, creating a multifactorial approach to renal and cardiovascular protection.

Olha Kravtsova, PhD, from the University of South Florida and the lead investigator of the study, emphasized the translational potential of these findings. The preclinical evidence supports broadening the clinical application of dual SGLT1/2 inhibitors beyond their conventional roles in heart failure and diabetes patients. Particularly for individuals grappling with salt-sensitive hypertension—a condition notoriously resistant to conventional antihypertensives—this therapeutic avenue heralds a promising alternative. Moreover, the newly uncovered metabolic pathways delineate exciting opportunities for further research, potentially unearthing novel drug targets centered on lipid metabolism and inflammatory modulation within the kidney.

The clinical implications extend beyond mere blood pressure control. By effectively lowering salt-induced hypertension and simultaneously reducing renal injury, dual SGLT1/2 inhibitors could alter the current management paradigms for chronic kidney disease. Given that hypertension remains a leading cause of CKD worldwide, a therapy that addresses the root contributors at a renal tubular level fits into a precision medicine framework. In light of these findings, nephrologists and cardiologists alike may soon consider the benefits of such combination inhibitors in comprehensive cardiovascular and renal care.

Intriguingly, the differential impact of SGLT1 versus SGLT2 blockade on sodium handling sheds light on the physiological role of proximal tubular segments in hypertensive pathophysiology. Whereas SGLT2 inhibition primarily affects early sodium and glucose reabsorption, the addition of SGLT1 blockade—localized to the more distal S3 segment—increases sodium excretion synergistically. This layered approach to disrupting sodium reabsorption pathways suggests a sophisticated mechanism for controlling volume overload and hypertension. These insights may also inform future drug development, guiding the design of agents with tailored segmental specificity.

Despite the promising outcomes, the study underscores the necessity for cautious progression toward human trials. Translational hurdles remain, given species differences in renal transporter expression and function. Nevertheless, the consistency of salt-sensitive hypertension mechanisms across mammals furnishes a robust preclinical foundation. The research presented at ASN Kidney Week 2025 invites the nephrology community to reassess the therapeutic landscape and fosters optimism for refined interventions in salt-related hypertensive and renal disorders.

The study titled “Dual SGLT1/2 Inhibition Attenuates Salt-Sensitive Hypertension and Kidney Injury More Effectively than SGLT2 Inhibition” represents a pivotal step in the nuanced understanding of renal glucose and sodium transport and its systemic effects. As researchers continue to unravel these complex interactions, the potential to transform clinical practice becomes increasingly tangible. This research signals a paradigm shift from singular to dual transporter inhibition, reflecting a comprehensive strategy to mitigate the multifactorial nature of hypertension and renal injury.

In conclusion, the dual inhibition of SGLT1 and SGLT2 by agents such as sotagliflozin offers a promising avenue for not only glycemic control but also for significant cardiovascular and renal protection. The findings from this rodent model study suggest that targeting multiple transporters in the kidney proximal tubule can more effectively suppress salt-sensitive hypertension and renal damage than current selective therapies. As new avenues open for addressing the metabolic and inflammatory underpinnings of hypertensive kidney disease, this line of research holds transformative potential for patients worldwide.

Join approximately 12,000 kidney specialists and healthcare professionals at ASN Kidney Week 2025 in Houston, TX, November 5–9, for the latest scientific discussions and updates in nephrology, including advances such as these that redefine kidney disease management. This global meeting remains a pivotal platform to exchange innovation, knowledge, and insight among leading experts aiming to improve patient outcomes in renal medicine.

Subject of Research: Effects of dual SGLT1/2 inhibition versus selective SGLT2 inhibition on salt-sensitive hypertension and kidney injury in a rat model
Article Title: Dual SGLT1/2 Inhibition Attenuates Salt-Sensitive Hypertension and Kidney Injury More Effectively than SGLT2 Inhibition
News Publication Date: November 7, 2025
Web References: www.asn-online.org
Keywords: Sodium-glucose co-transporter, SGLT1, SGLT2, salt-sensitive hypertension, kidney injury, dapagliflozin, sotagliflozin, proximal tubule, natriuresis, renal metabolism, lipid metabolism, inflammatory signaling

In an ambitious effort to tackle this clinical conundrum, investigators led by Dr. Shruti Gupta, MD, MPH, and Dr. David Leaf, MD, MMSc, of Brigham and Women’s Hospital have conducted a comprehensive multicenter cohort study that illuminates a potentially transformative approach to cisplatin nephrotoxicity prevention. Published recently in JAMA Oncology, the research outlines how intravenous magnesium administration on the same day as cisplatin chemotherapy can significantly diminish the risk of AKI, thus offering a pragmatic, cost-effective adjuvant therapy.

The nephrotoxic effects of cisplatin originate primarily from its accumulation in renal proximal tubular cells, where it induces oxidative stress, inflammation, and apoptosis. This cascade leads to impaired kidney function, often manifesting as an acute rise in serum creatinine and subsequent renal impairment. While hydration and dose adjustment remain cornerstones of clinical management, the precise molecular mechanisms of cisplatin-induced kidney injury have spurred exploration into targeted insights. Among these, magnesium’s role in renal physiology and detoxification pathways has garnered increasing attention.

Animal models have long suggested magnesium’s intervention potential, hypothesizing that magnesium supplementation promotes renal excretion of cisplatin and its metabolites, thereby attenuating tubular uptake and cytotoxicity. Despite this biological plausibility, robust evidence from large human populations has been lacking. Drs. Gupta and Leaf’s investigative team therefore designed a rigorous observational study leveraging data from five prominent U.S. cancer centers, encompassing nearly 14,000 patients receiving their first dose of intravenous cisplatin between 2006 and 2022.

This unprecedented cohort study stratified patients based on whether they received intravenous magnesium concurrently with the initial cisplatin administration. Approximately 30% of the cohort received IV magnesium. Employing meticulous statistical adjustments to control for confounding variables—including demographic factors, baseline kidney function, hydration protocols, and comorbidities—the researchers sought to isolate the independent association between magnesium receipt and the incidence of cisplatin-associated AKI.

The results were striking. After adjustment, patients receiving IV magnesium demonstrated a 20% reduction in the odds of developing acute kidney injury compared to those without magnesium supplementation. Importantly, this protective effect was consistent across multiple subgroups stratified by age, cancer type, cisplatin dose, and baseline renal risk. Sensitivity analyses further reinforced the robustness of these findings, underscoring magnesium’s potential as a nephroprotective agent in clinical oncology practice.

Mechanistically, magnesium’s protective role may be multifaceted. Given its critical involvement in cellular enzymatic reactions and membrane stabilization, magnesium infusion may mitigate oxidative damage induced by cisplatin metabolites. Additionally, magnesium appears to modulate renal tubular transporter activity, facilitating cisplatin clearance and reducing localized drug accumulation. This aligns with preclinical evidence that magnesium deficiency exacerbates cisplatin toxicity, while supplementation restores renal resilience.

The clinical implications of this study resonate strongly within oncology and nephrology communities. Magnesium is inexpensive, globally accessible, and carries a well-established safety profile. Integrating IV magnesium infusion into standard supportive care for patients scheduled to undergo cisplatin treatment could represent a straightforward yet impactful strategy to minimize nephrotoxicity. This approach promises to enhance patient quality of life, maintain chemotherapy dose intensity, and ultimately improve cancer treatment outcomes.

However, the authors are cautious to emphasize that despite compelling observational data, definitive confirmation requires randomized controlled trials (RCTs). Recognizing this gap, a pivotal RCT (NCT05730816) is underway at Brigham and Women’s Hospital, designed to prospectively evaluate the efficacy of IV magnesium in preventing cisplatin-associated AKI. Outcomes from this trial are eagerly anticipated and could catalyze paradigm shifts in chemoprotective protocols.

Beyond nephroprotection, magnesium’s role in oncology warrants continued exploration. Emerging evidence suggests systemic magnesium homeostasis influences tumor biology and patient tolerance to other cytotoxic agents. Future research may unravel additional benefits and mechanistic insights, potentially expanding magnesium’s therapeutic relevance beyond renal protection.

This groundbreaking study represents a remarkable example of translational research bridging bench and bedside. By harnessing real-world patient data from multiple institutions and incorporating mechanistic understanding from prior experimental studies, the investigators have delineated a promising pathway to ameliorate a long-standing clinical challenge.

As cisplatin remains a mainstay chemotherapy agent for numerous aggressive malignancies, reducing its adverse impact on patients’ kidneys is paramount. The findings reported by Gupta, Leaf, and colleagues ignite hope for clinicians and patients alike, signaling that a simple intervention such as intravenous magnesium administration could preserve kidney function without compromising anticancer efficacy.

Continued international collaboration and investment in nephro-oncology research will be critical to validate these findings and optimize protocols. Meanwhile, oncologists may consider the emerging evidence when developing individualized treatment plans, particularly for patients at heightened risk for renal complications.

In conclusion, the study titled “Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury: A Multicenter Cohort Study” published in JAMA Oncology marks a significant advance in supportive cancer care. It underscores the power of leveraging existing pharmacological agents to mitigate chemotherapy toxicity, offering a beacon of hope for safer, more tolerable cancer therapies worldwide.

Subject of Research: People
Article Title: Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury
News Publication Date: 24-Apr-2025
Web References: DOI: 10.1001/jamaoncol.2025.0756
References: Gupta S, et al. “Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury: A Multicenter Cohort Study” JAMA Oncology
Image Credits: Not provided
Keywords: Nephropathies, Kidney cancer, Magnesium, Cancer research, Cisplatin, Chemotherapy, Acute kidney injury, Nephrotoxicity